RxDoctor Payments Data

Gwendolyn Sumter-Davis

Family · Lebanon, PANPI 1962910372

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,075 of the $41,436 with a category attached, or 62.9%. Abbott accounts for 98.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2022 at $19,604 and has fallen 87.9% since, to $2,377 in 2024. Among family clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,436in general payments, 2019–2025

Across 157 payments — averaging $263.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$41K
  • Mannkind Corporation$195
  • Zealand Pharma US, Inc.$136
  • Novo Nordisk$113
  • Lilly USA, LLC$81
  • Dexcom, Inc.$39
  • plus $158 from 6 others

What the payments were for

  • Consulting fees$4501%
  • Speaking & faculty fees$26,07563%
  • Travel & lodging$11,82829%
  • Food & beverage$3,0837%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,436 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,790
Medicare patients
110
Services billed
722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate16$37,012
Clozapine40$2,016
Gabapentin51$1,333
Aripiprazole18$1,040
Duloxetine Hcl13$922
Quetiapine Fumarate27$844
Olanzapine28$816
Fluoxetine Hcl26$610
Metformin Hcl17$464
Divalproex Sodium12$451
Lorazepam11$430
Tamsulosin Hcl17$415
Lithium Carbonate18$380
Benztropine Mesylate13$378
Amlodipine Besylate22$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$81$81628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Lebanon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →